| Naslov: | CA19-9 serum levels predict micrometastases in patients with gastric cancer |
|---|
| Avtorji: | ID Jagrič, Tomaž (Avtor) ID Potrč, Stojan (Avtor) ID Miš, Katarina (Avtor) ID Plankl, Mojca (Avtor) ID Marš, Tomaž (Avtor) |
| Datoteke: | URL - Izvorni URL, za dostop obiščite http://ojs.szd.si/index.php/ro/article/view/2257/1872
PDF - Predstavitvena datoteka, prenos (793,76 KB) MD5: 7C8AAB04CB52B9FAE01DE7B978E682B6
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: | OI - Onkološki inštitut Ljubljana
|
|---|
| Povzetek: | Background. We explored the prognostic value of the up-regulated carbohydrate antigen (CA19-9) in node-negative patients with gastric cancer as a surrogate marker for micrometastases. Patients and methods. Micrometastases were determined using reverse transcription quantitative polymerase chain reaction (RT-qPCR) for a subgroup of 30 node-negative patients. This group was used to determine the cut-off for preoperative CA19-9 serum levels as a surrogate marker for micrometastases. Then 187 node-negative T1 to T4 patients were selected to validate the predictive value of this CA19-9 threshold. Results. Patients with micrometastases had significantly higher preoperative CA19-9 serum levels compared to patients without micrometastases (p = 0.046). CA19-9 serum levels were significantly correlated with tumour site, tumour diameter, and perineural invasion. Although not reaching significance, subgroup analysis showed better five-year survival rates for patients with CA19-9 serum levels below the threshold, compared to patients with CA19-9 serum levels above the cut-off. The cumulative survival for T2 to T4 node-negative patients was significantly better with CA19-9 serum levels below the cut-off (p = 0.04). Conclusions. Preoperative CA19-9 serum levels can be used to predict higher risk for haematogenous spread and micrometastases in node-negative patients. However, CA19-9 serum levels lack the necessary sensitivity and specificity to reliably predict micrometastases. |
|---|
| Ključne besede: | gastric cancer, micrometastases, CA19-9, rak (medicina), želodec, metastaze, diagnostika, antigeni, tumorski označevalci |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Datum objave: | 01.06.2016 |
|---|
| Založnik: | Association of Radiology and Oncology |
|---|
| Leto izida: | 2016 |
|---|
| Št. strani: | str. 204-211, VI |
|---|
| Številčenje: | Vol. 50, no. 2 |
|---|
| Izvor: | Ljubljana |
|---|
| PID: | 20.500.12556/DiRROS-18890  |
|---|
| UDK: | 616.3-006-07 |
|---|
| ISSN pri članku: | 1318-2099 |
|---|
| DOI: | 10.1515/raon-2015-0025  |
|---|
| COBISS.SI-ID: | 5741375  |
|---|
| Avtorske pravice: | by Authors |
|---|
| Opomba: | Soavtorji: Stojan Potrc, Katarina Mis, Mojca Plankl, Tomaz Mars;
|
|---|
| Datum objave v DiRROS: | 09.05.2024 |
|---|
| Število ogledov: | 1113 |
|---|
| Število prenosov: | 685 |
|---|
| Metapodatki: |  |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |